Sartori Simone B, Landgraf Rainer, Singewald Nicolas
Department of Pharmacology & Toxicology, Institute of Pharmacy & Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Peter-Mayr-Street 1, A-6020, Innsbruck, Austria.
Future Neurol. 2011 Jul 1;6(4):531-571. doi: 10.2217/fnl.11.34.
Mice are increasingly overtaking the rat model organism in important aspects of anxiety research, including drug development. However, translating the results obtained in mouse studies into information that can be applied in clinics remains challenging. One reason may be that most of the studies so far have used animals displaying 'normal' anxiety rather than 'psychopathological' animal models with abnormal (elevated) anxiety, which more closely reflect core features and sensitivities to therapeutic interventions of human anxiety disorders, and which would, thus, narrow the translational gap. Here, we discuss manipulations aimed at persistently enhancing anxiety-related behavior in the laboratory mouse using phenotypic selection, genetic techniques and/or environmental manipulations. It is hoped that such models with enhanced construct validity will provide improved ways of studying the neurobiology and treatment of pathological anxiety. Examples of findings from mouse models of enhanced anxiety-related behavior will be discussed, as well as their relation to findings in anxiety disorder patients regarding neuroanatomy, neurobiology, genetic involvement and epigenetic modifications. Finally, we highlight novel targets for potential anxiolytic pharmacotherapeutics that have been established with the help of research involving mice. Since the use of psychopathological mouse models is only just beginning to increase, it is still unclear as to the extent to which such approaches will enhance the success rate of drug development in translating identified therapeutic targets into clinical trials and, thus, helping to introduce the next anxiolytic class of drugs.
在焦虑症研究的重要方面,包括药物研发,小鼠正越来越多地取代大鼠成为模式生物。然而,将小鼠研究中获得的结果转化为可应用于临床的信息仍然具有挑战性。一个原因可能是,迄今为止的大多数研究使用的是表现出“正常”焦虑的动物,而非具有异常(升高)焦虑的“精神病理学”动物模型,后者更能紧密反映人类焦虑症的核心特征以及对治疗干预的敏感性,因此可以缩小转化差距。在此,我们讨论旨在通过表型选择、基因技术和/或环境操纵持续增强实验室小鼠焦虑相关行为的方法。希望这类具有更高结构效度的模型将为研究病理性焦虑的神经生物学和治疗提供更好的途径。我们将讨论焦虑相关行为增强的小鼠模型的研究发现实例,以及它们与焦虑症患者在神经解剖学、神经生物学、基因参与和表观遗传修饰方面的研究发现之间的关系。最后,我们强调借助小鼠研究确立的潜在抗焦虑药物治疗的新靶点。由于精神病理学小鼠模型的使用才刚刚开始增加,目前尚不清楚这些方法在将已确定的治疗靶点转化为临床试验从而帮助引入下一类抗焦虑药物方面能在多大程度上提高药物研发的成功率。